The continuous glucose monitors market grows rapidly due to fast customer

adoption.
 With increasing awareness of diabetes management, the market for continuous
glucose monitors (CGMs) is surging, driven by the higher adoption rate of the devices
from patients with type 1 diabetes (T1D) and insulin-dependent patients with type 2
diabetes (T2D).
 According to Global Data analysis, the CGM market is currently valued at $8.9bn. It
is expected to reach $15.4bn in 2030, with a compound annual growth rate (CAGR)
of 6.2% between now and 2030.
 Abbott Diabetes Care reported a strong growth of 33.0% led by its CGM, Freestyle
Libre, which saw sales of almost $1bn in the third quarter (Q3) of the year, mainly
driven by new customer growth. During the quarter, the device added more than
200,000 new users, bringing Libre’s total global user base to well in excess of 3.5
million users. Abbott’s major competitor on CGM, DexCom, reported revenue growth
of 30% versus the same quarter of the previous year to $650.2m, with organic growth
of 46% outside the US due to new customers.

 In india, medical devices are governed by CDSCO which is regulated by directorate

general of health services
 CDSCO is the only govt body which regulate the medical devices, many committees
had been set up and given their opinion and recommendation like the Mahelkar
Committee
 All these are now being taken into to form the Indian Medical Device Regulatory Act
(IMRDA) – in action on 31st dec,2009
 IMRDA Classification
1. Class A: Devices involving low risk levels
2. Class B: low to medium risks
3. Class C: moderate to high risks
4. Class D: high risks